Perforation of the Small Intestine after Introduction of Lenvatinib in a Patient with Advanced Hepatocellular Carcinoma

Lenvatinib is a first-line standard treatment for advanced hepatocellular carcinoma (HCC) with better anti-tumor effects than sorafenib, as shown by greater inhibition of the kinases of fibroblast growth factor receptor and vascular endothelial growth factor (VEGF) receptor. This report describes a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Gastroenterol
Autors principals: Suzuki, Naomi, Tajiri, Kazuto, Futsukaichi, Yuka, Tanaka, Shinichi, Murayama, Aiko, Entani, Toshiki, Kobayashi, Saito, Takahashi, Kosuke, Fujii, Tsutomu, Imura, Johji, Yasuda, Ichiro
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2020
Matèries:
Single Case
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7036537/
https://ncbi.nlm.nih.gov/pubmed/32110202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000505774
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars